164 related articles for article (PubMed ID: 36731243)
1. Low skeletal muscle mass predicts poor prognosis for patients with stage III cervical cancer on concurrent chemoradiotherapy.
Aichi M; Hasegawa S; Kurita Y; Shinoda S; Kato S; Mizushima T; Yokota NR; Miyagi E
Nutrition; 2023 May; 109():111966. PubMed ID: 36731243
[TBL] [Abstract][Full Text] [Related]
2. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
3. Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.
Lee J; Chang CL; Lin JB; Wu MH; Sun FJ; Jan YT; Hsu SM; Chen YJ
Clin Cancer Res; 2018 Oct; 24(20):5028-5036. PubMed ID: 29959140
[No Abstract] [Full Text] [Related]
4. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
[TBL] [Abstract][Full Text] [Related]
5. Sarcopenia Is an Important Prognostic Factor in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy.
Kiyotoki T; Nakamura K; Haraga J; Omichi C; Ida N; Saijo M; Nishida T; Kusumoto T; Masuyama H
Int J Gynecol Cancer; 2018 Jan; 28(1):168-175. PubMed ID: 29040185
[TBL] [Abstract][Full Text] [Related]
6. Sarcopenia Is Not a Prognostic Factor of Outcome in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy or Radiotherapy.
Matsuoka H; Nakamura K; Matsubara Y; Ida N; Nishida T; Ogawa C; Katsi K; Kanazawa S; Masuyama H
Anticancer Res; 2019 Feb; 39(2):933-939. PubMed ID: 30711978
[TBL] [Abstract][Full Text] [Related]
7. Low Skeletal Muscle Mass Is a Risk Factor for Aspiration Pneumonia During Chemoradiotherapy.
Endo K; Ueno T; Hirai N; Komori T; Nakanishi Y; Kondo S; Wakisaka N; Yoshizaki T
Laryngoscope; 2021 May; 131(5):E1524-E1529. PubMed ID: 33030229
[TBL] [Abstract][Full Text] [Related]
8. Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis.
Katsui K; Ogata T; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Sci Rep; 2021 Jun; 11(1):11882. PubMed ID: 34088965
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Third Cervical Vertebra Skeletal Muscle Index in Oral Cavity Cancer: A Retrospective Study.
Chang SW; Hsu CM; Tsai YH; Chang GH; Tsai MS; Huang EI; Tsai YT
Laryngoscope; 2021 Jul; 131(7):E2257-E2265. PubMed ID: 33433021
[TBL] [Abstract][Full Text] [Related]
10. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
11. Sarcopenia Is an Independent Prognostic Factor for Squamous Cell Carcinoma of the Cervix Treated With Concurrent Chemoradiotherapy.
Kise S; Arakaki Y; Kudaka W; Ariga T; Kinjo N; Kohatu H; Aoki Y
Anticancer Res; 2022 Oct; 42(10):4887-4893. PubMed ID: 36191992
[TBL] [Abstract][Full Text] [Related]
12. Extreme leanness, lower skeletal muscle quality, and loss of muscle mass during treatment are predictors of poor prognosis in cervical cancer treated with concurrent chemoradiation therapy.
Abe A; Yuasa M; Imai Y; Kagawa T; Mineda A; Nishimura M; Tonoiso C; Kubo A; Kawanaka T; Ikushima H; Iwasa T
Int J Clin Oncol; 2022 May; 27(5):983-991. PubMed ID: 35212828
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of the skeletal muscle index and systemic inflammatory index in patients with lymph node-positive breast cancer after radical mastectomy.
Tang R; Deng JP; Zhang L; Zhang WW; Sun JY; Chi F; Zhang J; Wu SG; He ZY
BMC Cancer; 2022 Mar; 22(1):234. PubMed ID: 35241010
[TBL] [Abstract][Full Text] [Related]
14. Defining reference values for low skeletal muscle index at the L3 vertebra level based on computed tomography in healthy adults: A multicentre study.
Kong M; Geng N; Zhou Y; Lin N; Song W; Xu M; Li S; Piao Y; Han Z; Guo R; Yang C; Luo N; Wang Z; Jiang M; Wang L; Qiu W; Li J; Shi D; Li R; Cheung EC; Chen Y; Duan Z
Clin Nutr; 2022 Feb; 41(2):396-404. PubMed ID: 34999334
[TBL] [Abstract][Full Text] [Related]
15. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.
Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G
Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766
[TBL] [Abstract][Full Text] [Related]
16. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma.
Iritani S; Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Suetsugu A; Shiraki M; Shimizu M; Moriwaki H
J Gastroenterol; 2015 Mar; 50(3):323-32. PubMed ID: 24817668
[TBL] [Abstract][Full Text] [Related]
17. Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy.
Cho WK; Yu JI; Park HC; Lim DH; Kim TH; Chie EK
Tumori; 2021 Jun; 107(3):247-253. PubMed ID: 32646298
[TBL] [Abstract][Full Text] [Related]
18. Low L3 skeletal muscle index associated with the clinicopathological characteristics and prognosis of ovarian cancer: a meta-analysis.
Jin Y; Ma X; Yang Z; Zhang N
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):697-705. PubMed ID: 36720459
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of ADC quantification for clinical outcome in uterine cervical cancer treated with concurrent chemoradiotherapy.
Gu KW; Kim CK; Choi CH; Yoon YC; Park W
Eur Radiol; 2019 Nov; 29(11):6236-6244. PubMed ID: 30980126
[TBL] [Abstract][Full Text] [Related]
20. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
